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Abstract
Background:	Knowledge	about	bacterascites	is	limited	and	management	guidelines	
are	based	on	small	patient	series.	The	purpose	of	this	study	was	to	add	further	insight	
into	 the	clinical	 characteristics,	microbiological	 findings,	 and	prognosis	of	patients	
diagnosed	with	bacterascites.
Methods:	Retrospective	analysis	of	patients	with	advanced	chronic	liver	disease	di-
agnosed	with	bacterascites	and	SBP	between	January	2003	and	August	2016.
Results:	In	this	study,	123	patients	were	included	with	142	episodes	of	bacterascites.	
The	median	MELD	score	was	20	and	clinical	symptoms	of	infection	were	present	in	
78%.	Empiric	antibiotic	treatment	was	initiated	in	68%.	In	26	untreated	patients	un-
dergoing	repeated	paracentesis,	42%	were	diagnosed	with	either	ongoing	bacteras-
cites	or	SBP.	The	presence	of	signs	or	symptoms	of	infection	was	not	an	independent	
predictor	for	mortality	or	spontaneous	resolution	of	infection.	The	1-	month	and	1-	
year	mortality	rates	of	the	123	patients	studied,	were	32%	and	60%,	respectively;	
these	results	were	in	line	with	data	pertaining	to	the	prognosis	of	SBP.
Conclusions:	Patients	with	bacterascites	and	SBP	are	highly	comparable	with	respect	
to	severity	of	 liver	disease	and	overall	prognosis.	 If	 left	untreated,	bacterascites	 is	
likely	to	persist	or	to	evolve	to	SBP	in	a	significant	proportion	of	patients.	The	results	
of	this	study	support	current	guidelines	regarding	the	treatment	of	ascitic	fluid	infec-
tion,	but	could	not	confirm	the	prognostic	relevance	of	symptomatic	disease	at	the	
time	of	diagnosis.	We	suggest	that	the	threshold	to	initiate	antibiotic	treatment,	in	
particular	in	cases	with	severely	advanced	liver	disease,	should	be	low.
K E Y W O R D S
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1  | INTRODUC TION
Bacterascites	is	defined	by	an	ascitic	fluid	polymorphonuclear	neu-
trophil	(PMN)	count	below	250/μL	and	a	positive	ascitic	fluid	culture	
results	 in	 the	 absence	 of	 an	 evident	 intra-abdominal,	 surgically	
treatable	 source	 of	 infection.1	 It	 is	 a	 different	 clinical	 entity	 than	
spontaneous	 bacterial	 peritonitis	 (SBP),	 which	 is	 characterized	 by	
a	 neutrophil	 reaction	 in	 ascites	 regardless	 of	 the	 bacterial	 culture	
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result.	Bacterascites	is	prevalent	in	8%-	11%	of	all	patients	with	cir-
rhosis	and	ascites,	and	the	clinical	significance	seems	to	vary	accord-
ing	to	how	the	infection	was	acquired.2-7
Several	hypotheses	have	been	proposed	to	explain	the	poten-
tial	 underlying	 pathophysiological	 mechanisms.	 The	 most	 com-
mon	 theory	 implicates	 that	 the	bacterial	 colonization	of	 ascites	
is	caused	by	bacterial	translocation	from	the	intestinal	 lumen	or	
by	 secondary	 translocation	 from	 a	 concomitant	 infection	 from	
extraintestinal	sites	(eg,	urogenital	or	respiratory	tract).	The	ab-
sence	 of	 an	 inflammatory	 response	 could	 be	 interpreted	 as	 an	
early	phase	of	SBP,	in	which	the	neutrophil	response	has	not	com-
menced	yet,	or	a	spontaneously	resolving	 infection,	determined	
by	good	host	defences	or	 less	virulent	pathogens.1,4	 In	this	con-
text,	 the	 term	 ‘symptomatic	 bacterascites’	 has	 been	 introduced	
for	patients	with	bacterascites	and	clinical	symptoms	of	infection,	
in	 order	 to	 identify	 those	 patients	who	may	 require	 treatment.	
Furthermore,	 bacterascites	 caused	 by	 commensal	 skin	 bacteria	
has	 been	 attributed	 to	 exogenous	 contamination	 of	 the	 ascitic	
fluid	 sample	 and	 bacterascites	with	multiple	 pathogens	may	 be	
caused	by	traumatic	paracentesis.2,3	The	indication	for	antibiotic	
treatment	of	bacterascites	is	generally	regarded	to	be	dependent	
on	 the	 supposed	pathophysiological	mechanism	and	 the	 clinical	
situation.
The	AASLD	 practice	 guideline	 regarding	 the	management	 of	
ascites	 states	 that	 patients	with	 ascites	 and	 convincing	 signs	 or	
symptoms	 of	 infection	 should	 receive	 empiric	 antibiotic	 treat-
ment.8	This	recommendation	is	based	on	one	study	with	36	cases	
of	bacterascites	receiving	a	follow-	up	paracentesis,	in	which	62%	
of	the	cases	spontaneously	resolved	and	38%	progressed	to	SBP.4 
The	EASL	 clinical	 practice	 guideline	endorses	 this	 recommenda-
tion	 and	 further	 states	 asymptomatic	 patients	 should	 undergo	
a	 second	 paracentesis	when	 culture	 results	 come	 back	 positive.	
Patients	in	whom	the	repeated	ascitic	PMN	count	is	greater	as	or	
equal	to	250/μL	should	be	treated	for	SBP,	and	the	remaining	pa-
tients	(ie,	PMN	count	below	250/μL)	should	be	followed	up.9	This	
guideline	 is	based	on	a	consensus	document	of	the	 International	
Ascites	Club	in	2000.1
Although	bacterascites	is	not	an	uncommon	condition,	relatively	
few	studies	on	prognostic	factors	and	outcome	of	this	ascitic	fluid	
infection	have	been	reported.2-7	Therefore,	the	purpose	of	this	study	
was	 to	 assess	 the	 clinical	 characteristics,	microbiological	 findings,	
and	 clinical	 course	 in	 consecutive	 patients	 diagnosed	with	 bacte-
rascites.	We	 further	 attempted	 to	 study	 the	 prognostic	 impact	 of	
bacterascites	 in	comparison	to	SBP,	and	to	define	the	most	 logical	
therapeutic	approach.
2  | PATIENTS AND METHODS
2.1 | Study design and data collection
All	consecutive	ascites	cultures	performed	in	patients	with	advanced	
chronic	 liver	 disease	 between	 January	 2003	 and	 August	 2016	 at	
Erasmus	 MC,	 University	 Medical	 Center,	 were	 retrospectively	
reviewed	to	identify	patients	fulfilling	the	diagnostic	criteria	for	bac-
terascites.	 The	Medical	 Ethics	 Committee	 Erasmus	MC,	 approved	
the	study	protocol	on	February	27th,	2017	and	stated	that	written	
informed	patient	consent	was	not	necessary	considering	the	design	
of	the	study.
All	 ascites	 samples	 obtained	 during	 the	 study	 period	were	 re-
viewed,	implying	that,	if	applicable,	multiple	bacterascites	episodes	
per	patient	were	taken	into	account.	The	lowercase	letter	n	was	used	
to	 indicate	the	number	of	patients	and	the	capital	 letter	N	for	the	
number	of	bacterascites	episodes.
Paracentesis	 was	 performed	 in	 patients	 with	 new-	onset	 asci-
tes,	 clinical	 deterioration,	 and	 large-	volume	 removal	 in	 refractory	
ascites.9	White	 blood	 cell	 (WBC)	 and	 PMN	 count	 in	 ascites	 were	
automatically	determined	and	aerobic	and	anaerobic	blood	culture	
bottles	 (Bactec®)	 were	 used	 for	 bacterial	 cultures.	 Blood	 cultures	
taken	within	two	hours	before	or	after	ascites	cultures	were	consid-
ered	to	be	concomitant.
Demographic,	 clinical,	 biochemical,	 and	 survival	 data	 from	pa-
tient	hospital	records	were	collected.
To	determine	the	prognostic	impact	of	bacterascites	in	compari-
son	with	reported	outcomes	of	SBP,	a	control	cohort	was	established	
with	patients	from	our	centre	with	SBP,	performed	as	described	in	
a	 previous	 publication.10	 In	 order	 to	 create	 homogenous	 groups	
for	 survival	 analyses,	patients	with	both	episodes	of	bacterascites	
and	SBP	were	 categorized	as	SBP	when	 the	 first	 ascites	 infection	
was	 SBP	 or	 bacterascites	 developed	within	 48	h	 to	 SBP.	 Patients	
with	 bacterascites	 developing	 SBP	 after	 48	h,	 but	 within	 30	days	
were	excluded	from	survival	analysis.	In	addition,	the	MELD	score-	
dependent	 relation	of	 the	prognosis	of	bacterascites	patients	was	
studied	and	compared	with	SBP	patients.11,12
Furthermore,	a	PubMed	search	was	performed	on	December	
1st,	2017	with	the	following	search	terms:	spontaneous	bacterial	
peritonitis	 (ALL)	 AND	 (outcome	 (ALL)	 OR	 mortality	 (ALL))	 AND	
prognos*	 (ALL).	 The	 studies	 were	 reviewed	 and	 included	 when	
the	following	criteria	were	met:	(1)	observational	studies,	(b)	study	
population	consisted	of	patients	with	SBP	defined	as	a	PMN	count	
of	 250/μL	or	 greater	 in	 ascites,	 (c)	minimum	 study	population	of	
50	 adult	 patients,	 (d)	 reporting	 survival	 analysis	 and	 1-	month	 or	
Key Points
•	 	Bacterascites	is	an	ascitic	fluid	infection	with	a	positive	
bacterial	 culture	 and	 PMN	 count	 below	 250/μL.	
Patients	 with	 bacterascites	 and	 SBP	 present	 with	 a	
similar	degree	of	liver	insufficiency	and	have	a	compa-
rable	poor	prognosis.	Current	guidelines	state	patients	
with	symptomatic	bacterascites	should	receive	antibi-
otic	 treatment.	However,	 the	present	study	could	not	
confirm	 the	 prognostic	 importance	 of	 presence	 of	
symptoms	at	the	time	of	diagnosis.
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in-	hospital	mortality	rate,	and	(e)	written	in	English.	Interventional	
studies	 (eg,	 randomized	controlled	 trials),	 studies	with	a	selected	
population	(eg,	HIV	patients),	and	abstracts	were	excluded.	Study	
and	 clinical	 characteristics	 were	 collected	 from	 the	 included	
studies.
2.2 | Definitions
Bacterascites	was	defined	as	an	ascitic	fluid	sample	with	a	PMN	count	
below	250/μL	and	a	positive	bacterial	culture,	in	the	absence	of	evi-
dence	 for	an	 intra-abdominal	 source	of	 infection.1	 Infection	acquisi-
tion	was	categorized	as	nosocomial	(infection	was	detected	after	48	h	
after	hospital	admission),	healthcare-	associated	 (<48	h	after	hospital	
admission	 in	 patients	with	 any	 90-	day	 prior	 healthcare	 contact),	 or	
community-	acquired	(within	48	h	after	hospital	admission	in	patients	
without	any	90-	day	prior	healthcare	contact).13	Ascites	was	graded	as	
diuretic-	responsive	or	diuretic-	refractory,	and	hepatic	encephalopathy	
(HE)	as	none,	or	West	Haven	grade	1-	4.	Patients	were	categorized	as	
symptomatic,	when	one	or	more	of	the	following	symptoms,	shown	to	
be	frequently	present	in	patients	with	SBP,	were	recorded:	abdominal	
discomfort	(feeling	of	fullness),	abdominal	pain/tenderness,	fever,	and	
a	change	in	mental	status	(recorded	as	HE	grade).14	Recent	gastroin-
testinal	 (GI)	bleeding	was	defined	as	a	diagnosed	upper	GI	bleeding	
in	the	72	h	prior	to	index	paracentesis.	During	the	study	period,	the	
standard	primary	antibiotic	treatment	in	patients	with	variceal	bleed-
ing	was	oral	norfloxacin	400	mg	twice	daily	or	intravenous	ceftriaxone	
1	g	daily	during	five	days.	The	secondary	prophylaxis	for	SBP	was	nor-
floxacin	400	mg	once	daily.8,9
2.3 | Statistical analysis
Continuous	variables	were	reported	as	mean	with	standard	devia-
tion	 (SD),	 after	 visual	 confirmation	 of	 approximate	 normality,	 and	
compared	using	the	Student’s	t-test.	Categorical	variables	were	re-
ported	as	count	with	proportion	and	compared	using	the	Chi-	square	
test.	A	two-	sided	P-	value	<0.05	was	considered	significant.
Transplantation-	free	 survival	was	 analysed	using	Kaplan-	Meier	
survival	 analysis.	 Follow-	up	 started	 at	 the	 time	 of	 the	 first	 ascitic	
fluid	analysis.	A	multivariable	logistic	regression	analysis	was	carried	
out	to	identify	predictors	for	treatment	of	bacterascites,	a	multivari-
able	 logistic	 regression	 analysis	 in	 the	 untreated	 patient	 group	 to	
identify	 risk	 factors	 for	worse	outcome	 (ie,	 liver-	related	death	be-
fore	culture	results	were	known,	SBP	development,	and	persisting	
bacterascites),	and	a	multivariable	Cox’s	proportional	hazard	analy-
sis	to	identify	independent	predictors	for	3-	month	mortality.	These	
analyses	were	 performed	 using	 the	 candidate	 predictor	 variables:	
age,	gender,	aetiology	of	 liver	disease,	MELD	score,	hepatocellular	
carcinoma,	gastrointestinal	bleeding,	HE,	grade	of	ascites,	symptoms	
of	infections,	immunosuppressive	medication	use,	antibiotic	prophy-
laxis	use,	Staphylococci	cultured,	and	PMN	count	in	ascites,	with	the	
addition	of	initiation	of	antibiotic	treatment	for	bacterascites	in	the	
Cox’s	 regression.	The	 regression	models	were	employed	using	 the	
backward	stepwise	selection	method	with	removal	testing	based	on	
the	 probability	 of	 the	 likelihood-	ratio	 statistic.	 Statistical	 analyses	
were	performed	using	 SPSS	Statistics	 for	Windows,	Version	21.0.	
(IBM	Corp.,	Armonk,	NY,	USA).
TABLE  1 Baseline	demographic	and	clinical	patient	
characteristics
Patients with 
bacterascites 
(n = 123)
Male,	n	(%) 76	(62%)
Age	in	years,	mean	(SD) 63	(±14)
Aetiology	of	cirrhosis,	n	(%)
Alcohol 35	(29%)
Viral 26	(21%)
Autoimmune-	related 19	(15%)
Alcohol	+	viral 10	(8%)
NASH 9	(7%)
Other 24	(20%)
MELD	score,	median	(IQR) 20	(14-	25)
Child-	Pugh	score,	median	(IQR) 8	(7-	10)
Child-	Pugh	class,	n	(%)
Class	A 30	(24%)
Class	B 61	(50%)
Class	C 32	(26%)
HCC,	n	(%) 21	(17%)
Sodium	(mmol/L),	mean	(SD) 136	(±8)
Creatinin	(μmol/L),	median	(IQR) 109	(73-	168)
Albumin	(g/L),	mean	(SD) 29	(±6)
Total	bilirubin	(μmol/L),	median	(IQR) 51	(26-	135)
INR,	mean	(SD) 1.7	(±0.7)
Ascites,	n	(%)
Diuretic-	responsive 33	(27%)
Diuretic-	refractory 90	(73%)
Hepatic	encephalopathy,	n	(%)
None 73	(59%)
West	Haven	grade	1-	2 32	(26%)
West	Haven	grade	3-	4 18	(15%)
PMN	count	in	ascites	(cells/μL),	mean	(SD) 48	(±61)
Protein	level	in	ascites	(g/L),	mean	(SD) 16	(±10)
Recent	GI	bleed,	n	(%) 35	(28%)
Use	of	norfloxacin,	n	(%) 27	(22%)
Primary	prophylaxis -	
Secondary	prophylaxis
Admission	status	during	paracentesis,	n	(%)
Inpatient 103	(84%)
Outpatient 20	(16%)
GI,	 gastrointestinal;	HCC,	 hepatocellular	 carcinoma;	 INR,	 international	
normalized	 ratio;	 IQR,	 interquartile	 range;	MELD,	model	 for	end-	stage	
liver	disease;	NASH,	nonalcoholic	steatohepatitis;	PMN,	polymorphonu-
clear	neutrophil;	SD,	standard	deviation.
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3  | RESULTS
3.1 | Patients
Between	 January	2003	 and	August	 2016,	 142	 episodes	 of	 bacte-
rascites	were	diagnosed	in	123	patients.	The	demographic,	clinical,	
and	laboratory	data	are	summarized	in	Table	1.	Patients	with	bacte-
rascites	were	mainly	male	with	a	mean	age	of	63	years	(±14)	and	a	
median	MELD	score	of	20	(IQR	14-	25).
3.2 | Bacterascites
The	infection	was	in	11%	of	the	bacterascites	episodes	community	ac-
quired,	in	55%	healthcare-associated,	and	in	34%	nosocomial	acquired.
One	or	more	clinical	symptoms	of	infection	were	present	in	the	
majority	 (78%)	 of	 patients	with	 bacterascites.	 Sole	 abdominal	 dis-
comfort	was	reported	by	18%,	HE	by	16%,	abdominal	pain	by	9%,	
and	fevers	or	chills	by	3%.	A	combination	of	these	symptoms	were	
present	in	32%:	13%	had	HE	and	abdominal	pain,	11%	HE,	fever	and	
abdominal	pain,	5%	fever	and	abdominal	pain,	and	3%	HE	and	fever.
Symptomatic	 patients	 had	 a	 similar	 age	 (mean	 64	 vs	 63	years;	
P = 0.907),	MELD	score	(median	20	vs	19	points;	P = 0.313),	serum	
creatinine	(median	106	vs	104	mmol/L;	P = 0.606)	and	PMN	count	in	
ascites	(median	23	vs	19	cells/μL;	P = 0.576)	compared	to	asymptom-
atic	patients.	Table	2	shows	additional	characteristics	in	relation	to	
the	presence	of	symptoms.	Monomicrobial	bacterascites	was	just	as	
likely	to	be	symptomatic	as	polymicrobial	bacterascites	(P = 0.660).	
Seventeen	 percent	 of	 patients	with	 bacterascites	were	 diagnosed	
with	 concomitant	 infections	 of	 the	 respiratory	 tract	 (6%),	 urinary	
tract	(5%),	or	skin	(6%).	Concomitant	blood	cultures	were	obtained	in	
42%	and	17%	of	symptomatic	and	asymptomatic	cases	respectively.	
The	proportion	of	positive	blood	cultures	did	not	statistically	differ	
between	the	groups.
Fourteen	patients	were	diagnosed	with	more	than	one	episode	
of	bacterascites.	In	five	patients,	the	second	episode	was	diagnosed	
within	5	days,	and	in	nine	patients	after	a	median	time	of	31	days.	Of	
these	14	patients,	nine	patients	died,	four	patients	received	a	liver	
transplant,	and	one	patient	was	lost	to-	follow-	up.	The	median	time	
till	one	of	the	endpoints	was	reached	was	74	days.	When	patients	
TABLE  2 Clinical	and	infection	characteristics	according	to	symptoms	associated	with	bacterascites	(N	=	142	episodes)
No symptoms 
(N = 31)
Any symptoms 
(N = 111)
Abdominal 
discomfort 
(N = 26)a
Abdominal pain 
(N = 52)a
New- onset/ 
worsening HE  
(N = 56)a
Fever  
(N = 32)a
Clinical	characteristics
MELD	score,	
median	(IQR)
19	(10) 20	(11) 17	(7) 21	(12) 23	(11) 25	(10)
PMN	count	in	
ascites	(cells/μL),	
median	(IQR)
19	(44) 23	(50) 28	(41) 30	(62) 21	(48) 40	(79)
Infection	characteristics
Acquisition	infection,	N	(%)
Community-	
acquired
4	(13%) 11	(10%) 3	(11%) 6	(12%) 3	(5%) 3	(9%)
Healthcare-
associated
15	(48%) 63	(57%) 14	(54%) 35	(67%) 30	(54%) 18	(56%)
Nosocomial 12	(39%) 37	(33%) 9	(35%) 11	(21%) 23	(41%) 11	(35%)
Repeated	paracen-
teses	after	48	h,	N	
(%)
15	(48%) 70	(63%) 17	(65%) 30	(58%) 32	(57%) 18	(56%)
Ascites	culture	
monomicrobial,	N	
(%)
26	(84%) 89	(80%) 21	(81%) 39	(75%) 46	(82%) 24	(75%)
Concomitant	infection,	N	(%)
Respiratory	tract 1	(3%) 8	(7%) 0 3	(6%) 7	(12%) 6	(19%)
Skin 1	(3%) 8	(7%) 1	(4%) 6	(12%) 4	(7%) 2	(6%)
Urinary	tract 0 7	(6%) 0 3	(6%) 3	(5%) 4	(12%)
Concomitant	blood	culture,	N	(%)
Non	taken 25	(80%) 65	(59%) 23	(88%) 24	(46%) 27	(48%) 10	(31%)
Negative 3	(10%) 21	(19%) 1	(4%) 13	(25%) 15	(27%) 8	(25%)
Positive 3	(10%) 25	(22%) 2	(8%) 15	(29%) 14	(25%) 14	(44%)
aPatients	could	have	multiple	symptoms	per	episode.	More	details	are	described	in	the	Results	section	in	the	paragraph	Bacterascites.
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with	a	single	episode	were	compared	with	patients	with	multiple	ep-
isodes,	 there	were	no	statistical	differences	 in	age,	gender,	MELD	
score,	PMN	count	in	ascites,	presence	of	symptoms,	antibiotic	pro-
phylaxis	use,	or	presence	of	a	GI	bleed.
In	36	of	142	bacterascites	episodes	(25.4%),	an	admission	to	the	
intensive	care	unit	 (ICU)	was	necessary;	14	cases	 (9.9%)	of	bacter-
ascites	were	diagnosed	on	the	ICU	and	in	22	cases	(15.5%)	patients	
were	admitted	to	the	ICU	after	organ	failure	development	following	
bacterascites	 diagnosis.	 ICU	 admission	was	 less	 than	 7	days	 in	 21	
cases,	between	7	and	14	days	in	six	cases,	between	14	and	30	days	
in	four	cases,	longer	than	30	days	in	five	cases.
3.3 | Microbiology
Monomicrobial	bacterascites	was	 found	 in	81%	of	all	 episodes,	 con-
sequently	multiple	pathogens	were	cultured	in	19%	of	all	episodes.	In	
polymicrobial	bacterascites,	two	or	three	different	organisms	were	cul-
tured.	Gram-	positive	bacteria	were	predominantly	cultured	in	monomi-
crobial	bacterascites.	The	177	species	cultured	in	monomicrobial	and	
polymicrobial	bacterascites	are	 listed	 in	Figure	1.	Staphylococci	were	
most	often	isolated	(43%),	followed	by	Streptococci	(17%),	Enterococci	
(14%),	and	Escherichia	(11%).	The	cultured	species	of	these	four	most	
common	found	genera	are	subtyped	in	Figure	S1.
Multidrug	 antibiotic-	resistant	 (MDR)	 organisms	 were	 isolated	
in	 25%	 of	 all	 episodes.	 Methicillin-	resistant	 Staphylococci	 were	
the	 most	 frequently	 found	 MDR	 organism	 (N	=	26),	 followed	 by	
extended-	spectrum	 beta-	lactamase	 (ESBL)	 producing	 bacteria	
(N	=	8).	A	similar	proportion	of	patients	using	primary	antibiotic	pro-
phylaxis	were	 infected	with	a	MDR	organism	(29.0%)	compared	to	
patients	without	prophylaxis	(23.1%)	(P = 0.506).
3.4 | Antibiotic therapy
In	 96	 (68%)	 of	 the	 total	 142	 episodes	 of	 bacterascites	 antibiotic	
treatment	was	initiated:	in	49	episodes	after	paracentesis	and	be-
fore	culture	results	became	available,	in	47	episodes	after	culture	
results	were	known.	In	16	cases,	the	antibiotic	treatment	was	mod-
ified	based	on	culture	results.	Amoxicillin-	clavulanic	acid	combina-
tion	was	most	often	prescribed	(30%),	followed	by	cephalosporin	
(14%)	 and	 vancomycin	 (10%).	 Symptomatic	 patients	 more	 often	
received	 treatment	 compared	 to	 asymptomatic	 patients	 (72%	 vs	
52%;	P = 0.031).	Patients	with	higher	MELD	score	 (HR	1.156	per	
point,	95%CI	1.060-	1.260,	P = 0.001),	higher	PMN	count	in	ascites	
(HR	1.017	per	point,	95%CI	1.005-	1.030,	P = 0.007),	an	 infection	
with	another	bacterial	genus	than	Staphylococci	(HR	3.512,	95%CI	
1.333-	9.253,	 P = 0.011),	 and	 a	 female	 gender	 (HR	 2.837,	 95%CI	
F IGURE  1 Type	of	pathogens	cultured	
in	142	bacterascites	episodes	classified	
by	genus 0 10 20 30 40 50 60 70 80
Candida
Salmonella
Bacteriodes
Citrobacter
Pantoea
Pseudomonas
Klebsiella
Moroxella
Enterobacter
Escherichia
Bacilli
Corynebacteria
Micrococci
Enterococci
Streptococci
Staphylococci
Fungus
Gram-negative bacteria
Gram-positive bacteria
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1.066-	7.547,	P = 0.037)	were	more	likely	to	receive	antibiotic	treat-
ment	for	bacterascites.
In	46	episodes	of	bacterascites,	antibiotic	treatment	was	not	
initiated.	 In	31/46	episodes	 (67%),	 patients	 had	 signs	or	 symp-
toms	of	infection.	A	total	of	111	episodes	of	bacterascites	were	
symptomatic.	 The	 ascitic	 PMN	 count	 in	 80	 patients	who	were	
treated	 with	 antibiotics	 was	 significantly	 higher	 (median	 31,	
range	 0-	235)	 than	 the	 PMN	 count	 (median	 13,	 range	 0-	71)	 in	
those	patients	(n	=	31)	who	did	not	receive	antibiotic	treatment	
(P = 0.002).	Figure	2	shows	a	flow	chart	of	the	clinical	course	of	
the	untreated	episodes	of	bacterascites.	Of	these	46	bacterasci-
tes	episodes,	the	patient	died	before	culture	results	were	known	
in	eight	cases,	in	all	these	cases	of	decompensating	liver	disease.	
These	eight	patients	had	a	median	MELD	score	of	29	 (IQR	18-	
30),	median	serum	creatinine	of	147	μmol/L	(IQR	100-	250),	and	
5/8	 patients	were	 admitted	 at	 the	 ICU;	 either	 before	 paracen-
tesis	 (two	 patients),	 or	 after	 paracentesis	 (three	 patients).	 SBP	
developed	in	six	cases,	and	bacterascites	persisted	in	five	cases.	
The	 latter	 group	 and	 those	 diagnosed	with	 SBP	were	 immedi-
ately	treated	with	antibiotics.	A	logistic	regression	analysis	was	
performed	 in	 the	untreated	patients	 to	 identify	 risk	 factors	 for	
liver-	related	death	before	culture	 results	were	known,	SBP	de-
velopment,	 and	 persisting	 bacterascites	 (19/46)	 compared	 to	
clinical	remission	(27/46).	We	found	that	MELD	score	(HR	1.286	
per	 point,	 95%CI	 1.071-	1.546,	 P = 0.007)	 and	 age	 (HR	 1.113	
per	 year,	 95%CI	1.027-	1.205,	P = 0.009)	were	 independent	 risk	
factors.
3.5 | Clinical course and outcome
The	survival	analyses	included	114	patients	with	bacterascites	and	
88	patients	with	SBP,	after	the	exclusion	of	patients	with	both	SBP	
and	bacterascites.	The	median	 follow-	up	 time	 in	114	patients	was	
38	days	 (IQR	15-	272).	 In	 this	 study	cohort,	27	patients	were	alive	
or	 lost	 to	 follow-	up,	 16	 patients	 received	 a	 liver	 transplant,	 and	
71	patients	died.	The	causes	of	death	were	 in	36	patients	 (50.7%)	
liver	 disease-	related,	 in	 29	 patients	 (40.9%)	 unknown,	 and	 in	 six	
patients	 (8.4%)	a	combination	of	 liver	disease-	related	and	nonliver	
disease-	related.
The	 cumulative	 mortality	 rates	 in	 bacterascites	 patients	 (1-	
month:	36%;	3-	month:	56%;	6-	month:	62%;	1-	year:	66%)	are	statis-
tically	comparable	to	that	reported	for	SBP	patients	(1-	month:	34%;	
3-	month:	54%;	6-	month:	67%;	1-	year:	77%)	(log-	rank	test	P = 0.397)	
(Figure	3).
The	 most	 important	 predictive	 factors	 for	 3-	month	 mortality	
after	bacterascites	diagnosis	were:	MELD	score	and	the	presence	of	
hepatic	encephalopathy	(Table	3).	Figure	4	shows	the	MELD	score-	
dependent	relation	of	survival	in	114	patients	with	bacterascites	and	
88	patients	with	SBP.
3.6 | Bacterascites in comparison with SBP 
in the literature
Our	literature	search	for	relevant	studies	of	SBP	identified	17	publi-
cations	(Table	4).10,15-30	The	reported	baseline	clinical	characteristics	
F IGURE  2 The	clinical	course	of	
patients	with	bacterascites	without	
antibiotic	treatment
Bacterascites without antibiotic treatment
N = 46
Symptomatic bacterascites
N = 31 
Patients died 
before culture 
results became 
available
N = 6
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N = 15 
Repeated paracentesis
N = 18
Expectative 
policy, 
clinical 
remission
N = 7
SBP
N = 4
Persistent 
bacterascites
N = 2
Spontaneously 
resolved
N = 12
Patients died 
before culture 
results became 
available
N = 2
Expectative 
policy, 
clinical 
remission
N = 5
Repeated paracentesis
N = 8
SBP
N = 2
Persistent 
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N = 3
Spontaneously 
resolved
N = 3
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including	age,	gender	distribution,	and	liver	disease	severity	scores	
of	SBP	were	comparable	to	those	 identified	 in	our	patient	popula-
tion	with	bacterascites.	In	addition,	the	cumulative	mortality	rate	in	
our	bacterascites	cohort	(1-	month:	36%;	6-	month:	62%;	1-	year:	66%)	
also	appears	comparable	 to	 that	 reported	 for	SBP	 (1-	month:	13%-	
49%;	6-	month:	52%-	59%:	1-	year:	49%-	70%).
4  | DISCUSSION
Bacterascites	is	an	infectious	complication	occurring	in	patients	with	
advanced	or	end-	stage	 liver	disease,	 and	 is	 associated	with	a	high	
short-	term	mortality	risk.	Bacterascites	tends	to	persist,	or	to	evolve	
to	SBP,	in	a	significant	proportion	of	cases.	Further,	our	findings	in-
dicate	that	bacterascites	diagnosed	in	in-	hospital	patients	has	great	
similarities	to	SBP.	In	particular,	patients	with	bacterascites	and	SBP	
present	with	a	similar	degree	of	liver	insufficiency	and	have	a	com-
parable	poor	prognosis.
In	our	cohort,	78%	of	patients	showed	clinical	symptoms	of	in-
fection,	which	is	reasonably	similar	to	the	rates	of	66%-	71%	in	pre-
viously	published	studies.4,6	Although	 it	 is	generally	accepted	 that	
SBP	is	frequently	accompanied	by	clinical	symptoms,	a	proportion	of	
13%-	32%	patients	with	SBP	has	been	reported	to	be	asymptomatic.6
With	the	results	of	this	study,	it	is	difficult	to	clearly	elucidate	the	
underlying	 pathogenesis	 of	 bacterascites.	 Gram-	positive	 bacteria	
were	frequently	isolated	in	bacterascites,	which	is	in	line	with	find-
ings	 from	other	bacterascites	 series.2,5-7	However,	only	a	minority	
of	episodes	of	bacterascites	was	considered	to	be	due	to	exogenous	
contamination.	 In	many	cases,	patients	 showed	evident	symptoms	
of	infection,	had	a	concomitant	positive	blood	culture,	or	there	were	
evidence	of	a	porte	d’entrée	from	the	skin	through	an	inserted	line	
or	catheter.	It	could	be	hypothesized	that	Gram-	positive	bacteria	are	
less	virulent	or	less	likely	to	induce	an	inflammatory	host	reaction,	
F IGURE  3 Comparable	cumulative	survival	curves	shown	for	
114	patients	with	bacterascites	(red	solid	line)	and	88	patients	with	
SBP	(blue	solid	line)	(log-	rank	test	P =	0.3973).	The	dashed	lines	
with	corresponding	colours	display	the	95%	confidence	interval
Number of patients at risk 
114  Bacterascites  
SBP  
29  28 
88 27          
48          
39          
40          
21     19
TABLE  3  Independent	predictive	factors	of	114	bacterascites	
patients	predicting	3-	month	mortality	(58	events)	identified	by	
multivariable	Cox-	regression	analysis
HR 95% CI P- value
MELD	score	(per	point) 1.099 1.082-	1.156 <0.001
Hepatic	encephalopathy
None	(reference) 1 0.002
West	Haven	grade	1-	2 1.411 0.697-	2.856
West	Haven	grade	3-	4 3.209 1.614-	6.381
CI,	 confidence	 interval;	 HR,	 hazard	 ratio;	MELD,	model	 for	 end-	stage	
liver	disease.
F IGURE  4 The	figure	shows	a	MELD	
score-	dependent	relation	for	the	3-	month	
survival	after	bacterascites	diagnosis	
of	114	patients	(blue	line).	The	survival	
of	88	patients	with	SBP	(red	line)	and	
advanced	chronic	liver	disease	without	
ascites	infection	(green	line)	are	plotted	
for	comparison
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which	has	been	previously	postulated	in	studies	analysing	patients	
with	 bacteremia.31,32	 Furthermore,	 traumatic	 paracentesis	 were	
highly	unlikely	to	explain	any	cases	of	bacterascites	in	our	cohort.	In	
all	polymicrobial	bacteracites,	a	maximum	of	three	different	organ-
isms	were	cultured	and	not	the	variety	of	bowel	flora	expected	after	
perforation.33	Thus,	it	is	more	likely	bacterascites	is	an	actual	coloni-
zation	of	ascites,	either	behaving	as	a	different	form	of	peritonitis	or	
with	a	large	probability	of	evolving	into	a	classic	infection.
Earlier	reports	have	suggested	bacterascites	patients	might	have	
higher	levels	of	bactericidal	and	opsonic	activity,	reflected	by	higher	
protein	concentrations	in	ascites,	preventing	a	full-	blown	inflamma-
tory	 response.4,34	 Despite	 the	 fact	 that	 protein	 concentrations	 in	
ascites	were	measured	on	an	irregular	basis	in	our	cohort,	the	mean	
protein	 level	of	16	g/L	does	not	 indicate	patients	are	deviant	from	
SBP	patients.35,36
Unexpectedly,	female	gender	was	one	of	the	factors	increasing	
the	odds	to	receive	antibiotic	treatment	for	bacterascites.	We	found	
a	correlation	between	female	gender	with	autoimmune-	related	liver	
disease	 aetiology	 and	 immunosuppressant	 use.	 Female	 patients	
were	 more	 likely	 to	 have	 autoimmune	 hepatitis,	 primary	 biliary	
cirrhosis,	or	nonalcoholic	 steatohepatitis	 and	more	often	used	 im-
munosuppressive	medication.	 Possibly,	 the	 threshold	 to	 prescribe	
antibiotic	treatment	for	bacterascites	is	lower	in	patients	using	im-
munosuppressive	medication.
One	of	the	goals	of	this	study	was	to	determine	the	clinical	course	
of	bacterascites.	 In	 two-	thirds	of	 the	 cases,	 the	 treating	physician	
decided	to	initiate	antibiotic	treatment.	However,	in	the	46	episodes	
not	 treated	with	antibiotics,	17%	died	before	 culture	 results	were	
known.	In	the	26	untreated	patients	undergoing	repeated	paracen-
tesis,	42%	were	diagnosed	with	either	ongoing	bacterascites	or	SBP.
The	results	of	this	study	do	not	support	the	importance	to	distin-
guish	clinically	between	symptomatic	and	asymptomatic	bacterasci-
tes.	The	proportion	of	untreated	bacterascites,	which	spontaneously	
resolved,	 was	 equal	 in	 symptomatic	 and	 asymptomatic	 patients.	
Furthermore,	 the	presence	of	 signs	or	 symptoms	of	 infection	was	
not	an	independent	predictor	for	mortality.
The	rate	of	25%	MDR	bacteria	found	in	all	bacterascites	episodes	
was	relatively	high	for	the	Netherlands,	but	it	is	in	line	with	current	
international	 microbiologic	 SBP	 studies	 reporting	 MDR	 bacteria	
rates	 of	 27%-	67%.37-39	 The	 involvement	 of	MDR	 bacteria	 in	 bac-
terascites	was	 not	 associated	 independently	with	mortality	 in	 our	
study.	Whether	there	is	an	independent	association	between	MDR	
bacteria	and	a	worse	prognosis	is	still	unclear	with	contrasting	find-
ings	in	studies	regarding	SBP.10,20,22,40,41
As	shown	in	Figure	4,	the	prognosis	after	bacterascites	is	worse	
than	the	reported	prognosis	based	on	the	MELD	score,	as	developed	
in	a	large	cohort	of	patients	with	advanced	chronic	liver	disease.11,12 
The	 relatively	high	 rate	of	 short-	term	mortality	 suggests	bacteras-
cites	 is	 either	 directly	 endangering	 the	 patient	 or	 a	 symptom	of	 a	
critical	condition.	Therefore,	these	data	suggest	that	these	patients	
should	be	medically	supported	by	all	available	means	including	anti-
biotic	treatment.	Timely	and	appropriate	antibiotic	treatment,	as	has	
been	proven	effective	 in	SBP,	seems	appropriate	 in	bacterascites.9 
Taking	 in	 consideration	 that	 27	 of	 the	 46	 untreated	 cases	 of	 bac-
terascites	 in	our	 cohort	 spontaneously	 resolved	bacterascites,	 this	
clinical	measure	might	induce	a	significant	over-	treatment.	This	study	
evidently	does	not	prove	that	treating	bacterascites	in	patients	with	
spontaneously	resolving	infection	will	improve	prognosis.	Although	
we	found	age	and	MELD	score	important	predictors	for	patients	with	
a	worse	clinical	course,	it	is	clinically	difficult	to	accurately	distinguish	
these	patients	from	patients	resolving	the	infection	spontaneously.
To	 the	 best	 of	 our	 knowledge,	 this	 is	 one	 of	 the	 first	 studies	
concentrating	solely	on	bacterascites	by	analysing	a	large	cohort	of	
consecutive	patients.	Our	cohort	with	123	patients	is	substantially	
larger	than	previously	reported	cohorts	including	18-	48	patients.2-7 
One	 of	 the	 limitations	 of	 this	 study	 is	 that,	 because	 of	 the	 retro-
spective	 design,	 the	 natural	 course	 of	 bacterascites	 could	 not	 be	
optimally	studied.	For	instance,	it	may	well	be	that	patients	received	
antibiotic	 treatment	 while	 the	 bacterascites	 would	 have	 resolved	
spontaneously.	 It	 should	 also	be	pointed	out	 that	 14	patients	 had	
multiple	bacterascites	episodes,	which	could	have	led	to	a	possible	
statistical	bias,	since	a	correlation	between	episodes	of	the	same	pa-
tient	was	ignored.	Prospective	studies	would	be	necessary	to	further	
define	the	natural	history	of	bacterascites	and	the	optimal	diagnostic	
and	therapeutic	strategy.	Such	studies	could	also	confirm	our	finding	
that	bacterascites	carries	a	mortality	risk	comparable	to	that	of	SBP.
In	conclusion,	bacterascites	is	a	complication	of	cirrhosis	compa-
rable	to	SBP	with	respect	to	clinical	background	and	prognosis.	Also	
considering	that	bacterascites	seems	to	persist	or	to	evolve	into	SBP	
in	a	substantial	proportion	of	cases,	with	no	clear	differences	in	the	
course	of	 symptomatic	 vs	 asymptomatic	 patients,	 our	 results	may	
suggest	that	the	(antibiotic)	treatment	strategy	in	bacterascites	and	
SBP	should	be	the	same.
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